Kyongbo Pharmaceutical Co Ltd (214390) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.51 Billion ≈ $3.06 Million USD) by net assets (₩145.28 Billion ≈ $98.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kyongbo Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Kyongbo Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Kyongbo Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kyongbo Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
-0.041x |
|
Hanshin Const
KO:004960
|
-0.050x |
|
DY Power Corp
KO:210540
|
0.044x |
|
Bastei Lübbe AG
XETRA:BST
|
-0.015x |
|
Mirae Asset Daewoo Co Ltd
KO:006805
|
-0.323x |
|
Lorne Park Capital Partners Inc
V:LPC
|
0.058x |
|
Chin Hung Int'
KO:002780
|
0.211x |
|
IMI PLC
LSE:IMI
|
0.259x |
Annual Cash Flow Conversion Efficiency for Kyongbo Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Kyongbo Pharmaceutical Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Kyongbo Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩146.15 Billion ≈ $99.05 Million |
₩149.12 Million ≈ $101.05K |
0.001x | -96.96% |
| 2023-12-31 | ₩144.38 Billion ≈ $97.85 Million |
₩4.84 Billion ≈ $3.28 Million |
0.034x | -52.39% |
| 2022-12-31 | ₩143.70 Billion ≈ $97.39 Million |
₩10.13 Billion ≈ $6.86 Million |
0.070x | -42.86% |
| 2021-12-31 | ₩145.70 Billion ≈ $98.74 Million |
₩17.97 Billion ≈ $12.18 Million |
0.123x | -7.45% |
| 2020-12-31 | ₩156.06 Billion ≈ $105.76 Million |
₩20.80 Billion ≈ $14.09 Million |
0.133x | -16.02% |
| 2019-12-31 | ₩149.16 Billion ≈ $101.09 Million |
₩23.67 Billion ≈ $16.04 Million |
0.159x | +2177.40% |
| 2018-12-31 | ₩149.01 Billion ≈ $100.98 Million |
₩-1.14 Billion ≈ $-771.31K |
-0.008x | -104.19% |
| 2017-12-31 | ₩141.51 Billion ≈ $95.90 Million |
₩25.81 Billion ≈ $17.49 Million |
0.182x | -6.84% |
| 2016-12-31 | ₩129.40 Billion ≈ $87.69 Million |
₩25.33 Billion ≈ $17.16 Million |
0.196x | +466.96% |
| 2015-12-31 | ₩122.82 Billion ≈ $83.23 Million |
₩4.24 Billion ≈ $2.87 Million |
0.035x | -85.29% |
| 2014-12-31 | ₩68.33 Billion ≈ $46.31 Million |
₩16.04 Billion ≈ $10.87 Million |
0.235x | -- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more